Mizokami A - Search Results

1

Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.

Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Fu Z, et al. Among authors: mizokami a. Prostate. 2006 Feb 15;66(3):248-56. doi: 10.1002/pros.20319. Prostate. 2006. PMID: 16175585 Free article.

2

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Mizokami A, et al. J Urol. 2000 Sep;164(3 Pt 1):800-5. doi: 10.1097/00005392-200009010-00053. J Urol. 2000. PMID: 10953159

3

Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.

Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Harada S, et al. Among authors: mizokami a. Prostate. 2001 Mar 1;46(4):319-26. doi: 10.1002/1097-0045(20010301)46:4<319::aid-pros1039>3.0.co;2-c. Prostate. 2001. PMID: 11241555

4

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Zhang J, et al. Among authors: mizokami a. J Clin Invest. 2001 May;107(10):1235-44. doi: 10.1172/JCI11685. J Clin Invest. 2001. PMID: 11375413 Free PMC article.

5

Cyclooxygenase-2 promotes prostate cancer progression.

Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Fujita H, et al. Among authors: mizokami a. Prostate. 2002 Nov 1;53(3):232-40. doi: 10.1002/pros.10152. Prostate. 2002. PMID: 12386924

6

Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system.

Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y, Mizokami A, Egawa M, Ogawa S, Hamada H, Namiki M. Miyagi T, et al. Among authors: mizokami a. J Gene Med. 2003 Jan;5(1):30-7. doi: 10.1002/jgm.317. J Gene Med. 2003. PMID: 12516049

7

Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.

Kitagawa Y, Koshida K, Mizokami A, Komatsu K, Nakashima S, Misaki T, Katsumi T, Namiki M. Kitagawa Y, et al. Among authors: mizokami a. Int J Urol. 2003 Jul;10(7):377-82. doi: 10.1046/j.1442-2042.2003.00640.x. Int J Urol. 2003. PMID: 12823692 Free article. Clinical Trial.

8

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. Mizokami A, et al. Cancer Res. 2004 Jan 15;64(2):765-71. doi: 10.1158/0008-5472.can-03-0130. Cancer Res. 2004. PMID: 14744796

9

Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.

Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nör J, McCauley LK, Taichman RS, Keller ET. Dai J, et al. Among authors: mizokami a. Cancer Res. 2004 Feb 1;64(3):994-9. doi: 10.1158/0008-5472.can-03-1382. Cancer Res. 2004. PMID: 14871830

10

Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.

Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Lu Y, et al. Among authors: mizokami a. Clin Exp Metastasis. 2004;21(5):399-408. doi: 10.1007/s10585-005-0056-6. Clin Exp Metastasis. 2004. PMID: 15672864 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

498 results

Search Page

Filters